Centessa Pharmaceuticals plc (NASDAQ:CNTA - Get Free Report) CEO Saurabh Saha sold 55,000 shares of the company's stock in a transaction dated Thursday, February 20th. The stock was sold at an average price of $15.93, for a total transaction of $876,150.00. Following the completion of the sale, the chief executive officer now directly owns 331,017 shares of the company's stock, valued at $5,273,100.81. The trade was a 14.25 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
Saurabh Saha also recently made the following trade(s):
- On Tuesday, January 21st, Saurabh Saha sold 55,000 shares of Centessa Pharmaceuticals stock. The stock was sold at an average price of $15.77, for a total transaction of $867,350.00.
- On Friday, December 20th, Saurabh Saha sold 55,000 shares of Centessa Pharmaceuticals stock. The stock was sold at an average price of $17.44, for a total transaction of $959,200.00.
- On Friday, December 6th, Saurabh Saha sold 87,496 shares of Centessa Pharmaceuticals stock. The stock was sold at an average price of $18.46, for a total transaction of $1,615,176.16.
- On Monday, November 25th, Saurabh Saha sold 299 shares of Centessa Pharmaceuticals stock. The stock was sold at an average price of $18.23, for a total transaction of $5,450.77.
- On Friday, November 22nd, Saurabh Saha sold 1,671 shares of Centessa Pharmaceuticals stock. The stock was sold at an average price of $18.24, for a total transaction of $30,479.04.
Centessa Pharmaceuticals Stock Up 5.3 %
Shares of CNTA traded up $0.84 during trading hours on Thursday, reaching $16.75. The company's stock had a trading volume of 762,948 shares, compared to its average volume of 793,520. The firm has a market cap of $2.21 billion, a price-to-earnings ratio of -10.95 and a beta of 1.53. Centessa Pharmaceuticals plc has a 1-year low of $7.75 and a 1-year high of $19.09. The company has a quick ratio of 21.52, a current ratio of 21.52 and a debt-to-equity ratio of 0.15. The company has a 50 day moving average of $16.71 and a two-hundred day moving average of $15.78.
Wall Street Analyst Weigh In
Several equities research analysts have commented on the stock. TD Cowen assumed coverage on shares of Centessa Pharmaceuticals in a research report on Tuesday, January 7th. They issued a "buy" rating on the stock. Guggenheim restated a "buy" rating on shares of Centessa Pharmaceuticals in a report on Monday, February 10th. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat, Centessa Pharmaceuticals presently has an average rating of "Buy" and an average price target of $25.83.
Check Out Our Latest Analysis on CNTA
Hedge Funds Weigh In On Centessa Pharmaceuticals
A number of large investors have recently made changes to their positions in CNTA. Janus Henderson Group PLC grew its stake in shares of Centessa Pharmaceuticals by 279.2% in the 4th quarter. Janus Henderson Group PLC now owns 4,909,487 shares of the company's stock valued at $82,218,000 after buying an additional 3,614,623 shares in the last quarter. Foresite Capital Management VI LLC bought a new stake in shares of Centessa Pharmaceuticals in the 4th quarter valued at approximately $20,994,000. Franklin Resources Inc. grew its stake in shares of Centessa Pharmaceuticals by 99.1% in the 3rd quarter. Franklin Resources Inc. now owns 2,302,546 shares of the company's stock valued at $38,360,000 after buying an additional 1,145,823 shares in the last quarter. Point72 Asset Management L.P. grew its stake in shares of Centessa Pharmaceuticals by 54.1% in the 3rd quarter. Point72 Asset Management L.P. now owns 2,715,663 shares of the company's stock valued at $43,423,000 after buying an additional 953,659 shares in the last quarter. Finally, Adage Capital Partners GP L.L.C. grew its stake in shares of Centessa Pharmaceuticals by 22.0% in the 4th quarter. Adage Capital Partners GP L.L.C. now owns 5,119,027 shares of the company's stock valued at $85,744,000 after buying an additional 924,027 shares in the last quarter. Institutional investors and hedge funds own 82.01% of the company's stock.
About Centessa Pharmaceuticals
(
Get Free Report)
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Centessa Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Centessa Pharmaceuticals wasn't on the list.
While Centessa Pharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
